Two studies released this week have renewed focus on CBD as a possible prophylactic option for stroke prevention as a preventative against behavioral deficits that might develop in those who use cannabis beginning in their adolescence.
One study, completed by Eugene Scharf of the Mayo Clinic in Rochester, Minnesota, and published in Cannabis and Cannabinoid Research, found that CBD may be an effective modality in the prevention of cerebrovascular disease. In particular, Scharf found that CBD is a modulator of activated hypothalamic CB1 cells, “exerting a homeostatic effect and reducing the hunger drive” in addition to improving weight loss. For those who suffer from atherosclerosis, in which plaque builds up inside a person’s arteries, CBD may affect type 2 CB receptors on neutrophils and macrophages in atherosclerotic plaques.
From “Just Say No” to “Just Add CBD?” Ok, such a change in drug education is unlikely to take place any time soon. But as new research demonstrates, adding CBD may counter some of the lingering effects that come with THC. The research looked at models of adolescent and adult mice. When exposed to THC as adolescents, the mice experienced a number of behavioral deficits, including repetitive and compulsive-like behavior. Other mice, who were exposed to a combination of THC with CBD, did not show the same deficits.
As the study itself says, “co-treatment with CBD prevents these deficits.” However, CBD on its own did not appear to change behavior from baseline. There were some other differences between THC administration in adolescent and adult mice. Adult mice had immediate—but not long term—impairment of object recognition and object/working memory. Chronic administration of both adult and adolescent mice produced a delayed increase in anxiety.
It’s likely that we’ll discover more uses for CBD as time goes by, and this week’s research into the possibility of CBD aiding in the prevention of strokes and behavioral deficits looks promising. Cannabidiol is the main ingredient of a drug that is being developed by GW Pharma called Epidiolex, a CBD based oil which is undergoing clinical trials and hopes to be available for pediatric patients suffering from Dravet syndrome. There’s already been some fascinating results for the drug, and as it becomes legal we are bound to see new research come out.
Featured image by Jennifer Martin.